New Gout Treatment Works Better for 61% of Patients

For millions of people living with gout, a new study offers hope that personalized treatment could mean fewer painful flare-ups and better results.

Researchers discovered that matching gout medication to the underlying cause of the disease worked significantly better than the standard one-size-fits-all approach. In a clinical trial of 196 men, 61% of patients who received benzbromarone reached healthy uric acid levels, compared to just 32% taking the standard medication febuxostat.

Gout happens when excess uric acid forms crystals in joints, causing sudden attacks of intense pain and swelling. Doctors typically prescribe xanthine oxidase inhibitors like febuxostat as the first treatment for everyone, regardless of what's causing their elevated uric acid levels.

But this trial took a different approach. Researchers focused specifically on patients whose gout stemmed from their kidneys not excreting enough uric acid. For these patients, benzbromarone, which helps the kidneys eliminate more uric acid, proved more effective even at low doses.

Over 12 weeks, patients taking benzbromarone showed lower average uric acid levels throughout the study. Nearly a quarter reached the strictest health target of less than 5 mg/dL, compared to only 9% in the standard treatment group.

Safety results were encouraging too. Neither group experienced serious side effects, and gout flares and kidney stones occurred at similar rates. Surprisingly, liver-related complications were actually less common with benzbromarone, affecting only 4% of patients compared to 15% taking febuxostat.

The Bright Side

This research represents a shift toward precision medicine in treating gout. Instead of giving everyone the same medication, doctors could soon test patients to understand why their uric acid is elevated, then choose the treatment most likely to work for their specific situation.

The approach mirrors successful strategies already used for other conditions, where personalized treatment based on underlying causes has transformed patient outcomes. For the estimated 9.2 million Americans living with gout, this could mean fewer painful attacks and better long-term joint health.

The study has limitations. It only included relatively young, healthy men and lasted just 12 weeks. Benzbromarone also isn't currently approved in the United States, though it's widely used in other countries.

Still, the results point to an important principle: understanding the root cause of a condition can lead to better treatment choices. As researchers continue exploring personalized approaches to gout, patients may soon have access to treatments tailored specifically to how their bodies work.

More effective gout treatment with fewer side effects could soon become reality for patients willing to work with their doctors to find the right match.